The Nobel Prize in Physiology or Medicine 2007
Level 5 - mechanism / opinion, no new human data
Narrative commentary and historical review of laboratory techniques without primary clinical data
OpenAlex W2092308256 · doi:10.1111/j.1365-3083.2007.02041.x
What was done
This editorial commentary describes the scientific background and development of gene targeting and knockout mouse technology recognized by the 2007 Nobel Prize in Physiology or Medicine. It outlines the historical integration of mouse embryonic stem cell isolation in vitro, retroviral and homologous recombination techniques for site-specific genomic modification, and subsequent refinements such as Cre-lox conditional and tissue-specific knockout systems.
What was found
The abstract provides a descriptive overview rather than quantitative experimental data. It notes that homologous recombination allows targeted replacement of specific nucleotide sequences, enabling the generation of homozygous knockout mice to evaluate gene loss, exon deletion, or point mutations. The commentary highlights that targeted modifications have been applied to approximately half of the estimated 22,000 mouse genes, yielding disease models across atherosclerosis, cystic fibrosis, cancer, and immunology (such as Ctla-4 knockout causing lethal lymphocyte proliferation and autoimmunity).
Why it matters
The paper summarizes the foundational principles of mammalian gene targeting, which transformed functional genomics and provided essential animal models for human disease mechanisms and immunological research.
Limits
This is a non-systematic, narrative historical summary containing no new experimental measurements, clinical data, or quantitative comparative analyses.
Cited by
- supports Oliver Smithies and Mario Capecchi received the Nobel Prize for homologous recombination decades before Jennifer Doudna and Emmanuelle Charpentier won for CRISPR.